For AML patients harboring FLT3-ITD, which is one of the most commonly detected cytogenetic abnormalities, several upstream inhibitors targeting FLT3 kinase achieved promising clinical outcomes [178]. This evidence concerns the gene FLT3 and acute myeloid leukemia.